Literature DB >> 10810461

Osteosarcoma in preadolescent patients.

M Rytting1, P Pearson, A K Raymond, A Ayala, J Murray, A W Yasko, M Johnson, N Jaffe.   

Abstract

The medical records of boys younger than 11 years and girls younger than 10 years of age with osteosarcoma of the pelvis or extremity were reviewed. Thirty patients were identified who were newly diagnosed but untreated for osteosarcoma. None of these patients had pulmonary metastases. The same four protocols were used to treat the patients in the current study as were used to treat adolescents. The event-free and overall survival was calculated and prognostic factors were assessed. The median followup time was 8 years (range, 6-14 years). The results were compared with the results of older patients treated with the same protocols and with published results. Fourteen patients had pulmonary metastases (47%); among these patients, four also had skeletal metastases (in two of the latter, skeletal metastases appeared before the pulmonary metastases). Event-free survival was 53% and overall survival was 57%. This result is comparable with current survival results in adolescent and older patients. Serum alkaline phosphatase and serum lactic dehydrogenase levels before treatment, height percentile greater than 50%, chemotherapy-induced tumor necrosis, surgical procedure, tumor site, tumor histologic features, and patient gender were not prognostic indicators. The prognosis for prepubertal patients with osteosarcoma is similar to the prognosis of their adolescent and older counterparts. There does not seem to be any indication to treat preadolescent patients with osteosarcoma using alternate therapies.

Entities:  

Mesh:

Year:  2000        PMID: 10810461     DOI: 10.1097/00003086-200004000-00007

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  30 in total

1.  Prognostic relevance of rosette-like features in osteosarcoma.

Authors:  K Okada; T Hasegawa; R Yokoyama; Y Beppu; E Itoi
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

2.  Osteosarcoma in children 5 years of age or younger at initial diagnosis.

Authors:  Jennifer Worch; Katherine K Matthay; John Neuhaus; Robert Goldsby; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

3.  RNAi-mediated silencing of AQP1 expression inhibited the proliferation, invasion and tumorigenesis of osteosarcoma cells.

Authors:  Zhong Wu; Shaohua Li; Jie Liu; Yongzhen Shi; Jianguang Wang; Dong Chen; Linjie Luo; Yongqiang Qian; Xiang Huang; Hua Wang
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

4.  MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET.

Authors:  Xinyu Li; Xufang Sun; Jing Wu; Zhihong Li
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

5.  Analysis of the molecular mechanism of osteosarcoma using a bioinformatics approach.

Authors:  Jianxun Yang; Ning Wang
Journal:  Oncol Lett       Date:  2016-08-29       Impact factor: 2.967

Review 6.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

Review 7.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

8.  Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients.

Authors:  Matthew T Harting; Kevin P Lally; Richard J Andrassy; Ara A Vaporciyan; Charles S Cox; Andrea Hayes-Jordan; Martin L Blakely
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

9.  Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy.

Authors:  Jingzhang Fan; Xin Yang; Zhenggang Bi
Journal:  Tumour Biol       Date:  2014-06-25

Review 10.  Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.

Authors:  Akio Sakamoto; Yukihide Iwamoto
Journal:  Rev Recent Clin Trials       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.